But suddenly, in January, the inhaler was no longer available ... many insurance companies don’t cover a generic alternative, and there’s a shortage of a similar branded alternative.

The FDA has finally approved the first generic of GlaxoSmithKline’s Advair blockbuster respiratory diseases inhaler ... regulator said at the time that there were only “minor deficiencies ...

Inhaler: peak plasma concentrations of 49ng/mL reached within 15 minutes. Nasal spray: maximum venous concentrations of 2–12ng/mL reached in 4–15 minutes. Nasal Spray antagonized by nasal ...

“In the United States, while 93% of Teva’s inhaler medicines are generic products with access at lower prices – particularly for insured patients – there still remain uninsured patients ...